Charles River Laboratories Inte found using ticker (CRL) now have 15 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 281 and 222 with the average target price sitting at 258.53. Now with the previous closing price of 243.08 this is indicating there is a potential upside of 6.4%. There is a 50 day moving average of 236.1 and the 200 moving average now moves to 213.89. The company has a market cap of $11,946m. Find out more information at: http://www.criver.com
Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International is based in Wilmington, Massachusetts.
You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.